Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Liabilities and Shareholders Equity (2016 - 2026)

Pharma-Bio Serv filings provide 16 years of Liabilities and Shareholders Equity readings, the most recent being $13.5 million for Q1 2026.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 15.73% to $13.5 million in Q1 2026 year-over-year; TTM through Jan 2026 was $54.7 million, a 16.65% decrease, with the full-year FY2025 number at $13.7 million, down 16.2% from a year prior.
  • Liabilities and Shareholders Equity hit $13.5 million in Q1 2026 for Pharma-Bio Serv, down from $13.7 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $22.9 million in Q1 2023 to a low of $13.5 million in Q1 2026.
  • Median Liabilities and Shareholders Equity over the past 5 years was $19.2 million (2024), compared with a mean of $18.0 million.
  • Biggest five-year swings in Liabilities and Shareholders Equity: dropped 28.91% in 2022 and later rose 3.74% in 2023.
  • Pharma-Bio Serv's Liabilities and Shareholders Equity stood at $20.7 million in 2022, then decreased by 3.63% to $19.9 million in 2023, then dropped by 18.14% to $16.3 million in 2024, then fell by 16.2% to $13.7 million in 2025, then decreased by 0.77% to $13.5 million in 2026.
  • The last three reported values for Liabilities and Shareholders Equity were $13.5 million (Q1 2026), $13.7 million (Q4 2025), and $13.6 million (Q3 2025) per Business Quant data.